Black Rock Inc. Galera Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Galera Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 357,192 shares of GRTX stock, worth $78,582. This represents 0.0% of its overall portfolio holdings.

Number of Shares

357,192

Previous 357,622 0.12%

Holding current value

$78,582

Previous $50,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.14 - $0.27 $60 - $116	-430 Reduced 0.12%	357,192 $50,000
Q4 2023 Feb 13, 2024	SELL	$0.09 - $0.27 $1,171 - $3,515	-13,021 Reduced 3.51%	357,622 $50,000
Q3 2023 Nov 13, 2023	SELL	$0.17 - $3.0 $704 - $12,438	-4,146 Reduced 1.11%	370,643 $66,000
Q2 2023 Aug 11, 2023	BUY	$2.5 - $3.42 $138,172 - $189,019	55,269 Added 17.3%	374,789 $1.17 Million
Q1 2023 May 12, 2023	BUY	$1.48 - $2.68 $32,851 - $59,487	22,197 Added 7.47%	319,520 $817,000

Q4 2022 Feb 13, 2023	SELL	$1.34 - $1.76 $19,975 - $26,236	-14,907 Reduced 4.77%	297,323 $443,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $2.1 $2,793 - $5,100	-2,429 Reduced 0.77%	312,230 $543,000
Q2 2022 Aug 12, 2022	SELL	$1.24 - $2.39 $8,224 - $15,852	-6,633 Reduced 2.06%	314,659 $410,000
Q1 2022 May 12, 2022	BUY	$2.01 - $4.19 $299,998 - $625,370	149,253 Added 86.76%	321,292 $765,000
Q4 2021 Feb 10, 2022	SELL	$1.27 - $8.28 $17,616 - $114,851	-13,871 Reduced 7.46%	172,039 $790,000
Q3 2021 Nov 09, 2021	BUY	$7.04 - $10.49 $5,413 - $8,066	769 Added 0.42%	185,910 $1.51 Million
Q2 2021 Aug 11, 2021	BUY	$6.08 - $10.44 $1.13 Million - $1.93 Million	185,141 New	185,141 $1.82 Million

Others Institutions Holding GRTX

# of Institutions

Shares Held

10.7M

Call Options Held

10.3K

Put Options Held

View Full List

About Galera Therapeutics, Inc.

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $5.9M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

More about GRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account